Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction
Clinical Breast Cancer · 2026-09 · 26 (9) · 66-74
DOI: 10.1016/j.clbc.2026.07.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-09. Verfasst von Victoria Kong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammaplasty, Postoperative Complications, Diabetes Mellitus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Autologous breast reconstruction (ABR) offers superior quality of life compared with implant-based reconstruction or mastectomy alone but carries substantial perioperative risk. Diabetes mellitus is a known predictor of postoperative morbidity but is often treated as a binary variable, obscuring differences between patients on oral antihyperglycemic agents (diabetes managed with oral antihyperglycemic agents [DM-ORAL]) and insulin (diabetes requiring insulin therapy [DM-INS]). MATERIALS AND METHODS: Using the National Surgical Quality Improvement Program, we identified female breast cancer patients undergoing immediate ABR (2008-2021). Diabetes status was categorized as nondiabetic, DM-ORAL, or DM-INS. Primary outcomes were 30-day adverse events, reoperation, unplanned readmission, and surgical and medical complications. Groups were compared and multivariable regression used to adjust for confounders. RESULTS: Of 8121 patients, 559 (6.9%) had diabetes, including 457 (81.8%) DM-ORAL and 102 (18.2%) DM-INS. Diabetes prevalence increased over time with a 0.3 percentage-point annual rise (R2 = 0.58; P = .003), driven mainly by DM-ORAL (R2 = 0.52; P = .005), while DM-INS showed a nonsignificant trend (R2 = 0.28; P = .07). Compared with nondiabetic patients, diabetics had higher overall complication rates (34.7% vs. 24.1%), including medical (6.4% vs. 2.8%) and surgical complications (23.6% vs. 15.2%) (all P < .0001). Within diabetics, DM-INS demonstrated higher morbidity, including unplanned readmission (14.7% vs. 6.3%, P = .008) and superficial infection (10.8% vs. 5.3%, P = .04) compared to DM-ORAL. On multivariable analysis, diabetes independently predicted complications (OR 1.4), with higher risk in DM-INS (OR 1.9) than DM-ORAL (OR 1.3); DM-INS more than doubled surgical complication risk (OR 2.5). CONCLUSION: Diabetes is a significant but heterogeneous risk factor in ABR, with insulin-treated patients at particularly elevated perioperative risk, supporting treatment-specific risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT.
- Department of Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
- Department of Hand, Plastic, and Reconstructive Surgery, Microsurgery, Burn Trauma Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany.
- Hospital Santa Casa de Misericórdia Rio de Janeiro, Instituto Ivo Pitanguy, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro, Brazil.
- Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT; Department of Plastic, Reconstructive, Aesthetic, and Hand Surgery, University Hospital Basel, Basel, Switzerland.
- Department of Plastic, Reconstructive, Aesthetic, and Hand Surgery, University Hospital Basel, Basel, Switzerland.
Zitieren
APA
Kong, V., Jiang, J., Niederegger, T., Schaschinger, T., Sofo, G., Wildberger, M. A., Fabi, A., Schweizer, T., Kappos, E. A., Schmauss, D., Machens, H. G., Diatta, F., Kauke-Navarro, M., & Knoedler, S. A. (2026). Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction. Clinical Breast Cancer, 26(9), 66-74. https://doi.org/10.1016/j.clbc.2026.07.020
Vancouver
Kong V, Jiang J, Niederegger T, Schaschinger T, Sofo G, Wildberger MA, et al. Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction. Clinical Breast Cancer. 2026;26(9):66-74. doi:10.1016/j.clbc.2026.07.020
BibTeX
@article{Kong2026,
author = {Kong, Victoria and Jiang, Jun and Niederegger, Tobias and Schaschinger, Thomas and Sofo, Giuseppe and Wildberger, Miguel Aranda and Fabi, Adriano and Schweizer, Thierry and Kappos, Elisabeth A and Schmauss, Daniel and Machens, Hans-Guenther and Diatta, Fortunay and Kauke-Navarro, Martin and Knoedler, Samuel A},
title = {Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {9},
pages = {66--74},
doi = {10.1016/j.clbc.2026.07.020}
}
EUVIMED